NCT06904066 — National Cancer Institute (NCI) neoantigen vaccine trial
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Registry record
| Registry ID | NCT06904066 ↗ |
|---|---|
| Lead sponsor | National Cancer Institute (NCI) |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Recruiting |
| Indication | Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms, Hematopoietic Malignancies, Dysmyelopoietic Syndromes, Hematopoetic Myelodysplasia, Myeloid Leukemia, Acute, Nonlymphoblastic Leukemia, Acute, Leukemia, Lymphocytic, Acute |
| Enrollment | 86 participants (target) |
| Start date | 2026-09-09 |
| Primary completion | 2029-04-30 (est.) |
| Last registry update | 4 Sept 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06904066), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06904066?
NCT06904066 (Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies) is registered on ClinicalTrials.gov as Phase 1, sponsored by National Cancer Institute (NCI).
Is NCT06904066 recruiting?
As of the 2026-09-04 registry update, NCT06904066 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06904066?
The lead sponsor is National Cancer Institute (NCI).
What condition does NCT06904066 study?
The registered conditions are Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms, Hematopoietic Malignancies, Dysmyelopoietic Syndromes, Hematopoetic Myelodysplasia, Myeloid Leukemia, Acute, Nonlymphoblastic Leukemia, Acute, Leukemia, Lymphocytic, Acute. Primary completion is listed as 2029-04-30 (estimated).
Are results available for NCT06904066?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06904066.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.